Print
Email
Print Edition StoriesThursday, August 21, 2008
BioVex granted U.K. study of genital herpes vaccine
By Mass High Tech Staff
BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has received British approval to begin a Phase 1 clinical study of its genital herpes vaccine treatment, ImmunoVEX HSV2.
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the clinical trial application to examine safety and immunogenicity of the vaccine.
ImmunoVEX HSV2 operates by allowing the human immune system to build up a response to the presence of genital herpes, after the vaccine has effectively removed the gene that prevents herpes from making contact with the immune system.
Privately-held BioVex last reported closing a $35 million Series E round of funding in November 2007. The proceeds, the company said, would fund Phase 3 clinical trials of its lead melanoma drug as well as trials for its treatments for head and neck, and pancreatic cancers. BioVex also reported that the round would be used to advance studies of its ImmunoVEX HSV2 vaccine for genital herpes.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
